VEEVA SYSTEMS INC
VEEVA SYSTEMS INC (VEEV) Stock News
The latest VEEV headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.
- Zacks Investment Research·Neutral
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It
Veeva Systems, a cloud-based software provider for the life sciences industry, is trending among investors. The stock has returned +1.7% over the past month, outperforming the S&P 500's -0.4% change. With earnings expected to grow 13.8% this fiscal year and 10.2% next year, along with strong revenue growth forecasts of 15.3% and 12% respectively, Veeva has consistently beaten consensus estimates. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term.
- Zacks Investment Research·
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.